Third Quarter 2026 Earnings Call - WAVE LIFE SCIENCES INC

Explicit Guidance:

• Cash Runway: Cash, cash equivalents, and marketable securities of $431 million are expected to fund operations through the third quarter of 2028.
• Near-term Cash Inflow: An incremental $12 million milestone payment from GSK is due in the fourth quarter of 2026.
• Pipeline Milestone Timing: WVE-008 (PNPLA3) CTA submission is on track for 2026.

Business-Segment Outlook:

• WVE-007 (Obesity - Inhibin E):
  • Phase 2a Monotherapy: Enrollment underway in a target population (BMI 35–50, comorbidities); data readout for the 12-month regulatory threshold (5% weight loss) is expected as early as year-end, with potential data analysis for a 3-month interim body composition readout later this quarter.
  • Combination Therapy: Phase 2a trial with trisepatide initiated in Q3 2026; evaluating 240mg and 400mg doses of WVE-007 in combination with weekly trisepatide in patients with BMI 35–50 and Type 2 Diabetes.
  • Maintenance Therapy: Trial to evaluate WVE-007 as post-incretin maintenance to prevent weight regain is on track to initiate in Q4 2026.
  • Dosing: SPINA siRNA design supports once or twice-yearly dosing; upcoming 600mg Phase 1 MAD data (Q4 2026) will characterize potency, duration, and safety.
• WVE-006 (AATD - RNA Editing):
  • Registrational Strategy: Planning a single two-year trial with a one-year interim analysis for potential accelerated approval, avoiding a separate confirmatory trial.
  • Data Readouts: 600mg monthly dosing data from the "Restoration 2" trial expected in Q4 2026 to inform optimal dose and interval for the pivotal study.
  • Endpoints: Focus on restoring MZ-like phenotype (≥50% M protein, decreased Z, acute phase response); potential use of CD densitometry (accepted in EU) for rapid approval pathways.
• WVE-008 (PNPLA3 - RNA Editing): Advancing toward clinic in 2026; first-in-human study planned to leverage genotyped populations for efficient enrollment in homozygous I148M carriers.
• GSK Collaboration: GSK selected a novel development candidate (siRNA) in Q3 2026; three additional programs remain in the collaboration pipeline.

Market and Competitive Outlook:

• Obesity Landscape: WVE-007 positioned as a differentiated alternative to GLP-1s (e.g., incretins) by driving fat loss without muscle loss, addressing the ~40% muscle loss and high discontinuation rates associated with current standards of care.
• Value Proposition: Potential to enable GLP-1 down-titration and "off-ramp" strategies to prevent the ~70% weight regain observed post-GLP-1 discontinuation.
• AATD Landscape: RNA editing (WVE-006) positioned as a preferred first-line therapy over DNA editing (safety/efficacy concerns) and silencing approaches (lack of protein restoration); distinct from current IV augmentation which fails to address liver disease.
• Liver Disease (MASH/PNPLA3): No approved therapies address the underlying PNPLA3 I148M mechanism directly; WVE-008 aims to correct the variant rather than silence the gene, potentially avoiding residual inflammation/fibrosis risks associated with silencing.

Macro / Industry Outlook:

• Regulatory Trend: FDA and industry moving toward harmonization in rare disease (e.g., Rare Disease Hub); expectation of increased alignment between CBER and CDER regarding endpoints and trial designs.
• Regulatory Nuance: Anticipated shift by regulators (FDA/EMA) and patient advocates to focus on "healthy weight loss" (body composition: visceral fat reduction, muscle preservation) rather than scale weight alone.
• Assay Standardization: FDA demonstrated flexibility and acceptance of WAVE's LC-MS assay for AATD development, validating the use of well-characterized proprietary assays throughout clinical programs.

Strategic Initiatives:

• Commercial Expansion: Monica Vinuk joined as Chief Business Officer (from Sanofi) to lead corporate development, expand partnering opportunities for clinical and preclinical assets, and drive next-phase growth.
• Research Day: Upcoming event (next week) to detail hepatic/extrahepatic capabilities, RNA editing innovation, and bifunctional modalities; Dr. Arun Sanyal to present on PNPLA3.
• Partnership Strategy: Continued exploration of value creation through partnering on clinical and preclinical portfolios; GSK collaboration validated by candidate selection and platform capabilities.

Risks and Headwinds to Outlook:

• Trial Design Risks: Regulatory acceptance of biomarker-based accelerated approval (AATD) requires sustained performance to full approval within the single-trial framework.
• Competition: Competitors (e.g., Arrowhead, Takeda) pursuing siRNA/silencing approaches in AATD; reliance on specific patient registries and KOL engagement for enrollment speed in AATD.
• Dosing Optimization: Uncertainty regarding whether 600mg dose or bi-weekly frequency (vs. monthly) will be optimal for WVE-006, pending Q4 data.
• Obesity Trial Endpoints: Regulatory pathway for "body composition" endpoints beyond simple weight loss remains evolving, though WAVE is actively engaging with the agency.
• Clinical Uncertainty: Maintenance therapy efficacy magnitude (prevention of fat regain) not yet quantified in human trials.

Management Tone on the Future:

• Confidence: High confidence in WVE-007's ability to cross the 5% weight loss threshold in Phase 2a due to higher baseline adiposity in the trial population matching Phase 2/3 profiles.
• Efficiency: Emphasis on capital efficiency and speed to market via innovative trial designs (single trial for AATD approval) and early regulatory alignment.
• Validation: Strong sentiment that the Nobel Prize in Chemistry validates the importance of stereochemistry and chirality, reinforcing WAVE's proprietary chemistry advantage over competitors.
• Growth Outlook: Positive outlook on expanding the GSK partnership and leveraging the new CBO to accelerate commercial and partnering momentum.

Miscellaneous:

• Financials (Reference only): Q3 2026 revenue $13.2M (up from $7.6M), R&D expense $53.8M, G&A $25.4M, Net loss $61.9M.
• Specific Trial Details: WVE-007 Phase 2a Monotherapy includes 4 cohorts (2 doses, 2 populations with/without T2D), 40 participants each, followed for 12 months.
• Geographic Scope: WVE-006 AATD trial will be global, with specific consideration for EU acceptance of CD densitometry endpoints.